

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 September 2022 (15.09.2022)



(10) International Publication Number
WO 2022/192403 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/019556

(22) International Filing Date:

09 March 2022 (09.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/158,584 09 March 2021 (09.03.2021) US

(71) Applicant: **XENCOR, INC.** [US/US]; 111 West Lemon Avenue, Monrovia, CA 91016 (US).

(72) Inventors: **FABER, Matthew, S.**; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). **LEE, Sung-Hyung**; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). **KIM, Yoon, Kyung**; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). **QI, Jing**; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). **AVERY, Kendra, N.**; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). **CHU, Seung, Y.**; c/o Xencor, Inc., 111 West

Lemon Avenue, Monrovia, CA 91016 (US). **NISTHAL, Alex**; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). **BERNETT, Matthew, J.**; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). **DESJARLAIS, John, R.**; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). **BORCHERT, Chad**; c/o Bio-Techne Corporation, 614 McKinley Place NE, Minneapolis, MN (US).

(74) Agent: **NGUYEN, Louis-Vu, T.** et al.; Morgan, Lewis & Bockius, LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6

(57) Abstract: Provided herein are CLDN6 binding domains, and anti-CLDN6 x anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

Figure 17A





Figure 17B



WO 2022/192403 A1

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*